Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.

Baseline LVEF decreased from 65.3±0.5 to 64.3±0.6 at cycle 4 of the DOX treatment (p=0.549) and to 63.8±0.9 (p=0.053) after 12 months (Figure 1 ) with a tendency toward significance.

also in 340 other papers

This reduction in LVEF did not reach statistical significance, probably due to the small sample size, but it was consistent with the reduction of similar magnitude (2.6%) observed in the recent PRADA trial [ 22 ].

also in 111,027 other papers